[177Lu]DOTA-anti-CD20: Labeling and pre-clinical studies

Compartmental and dosimetric studies of anti-CD20 labeled with 188Re

“…The parameters used in the computations were: radius of the tumor, point of interest Fig. 1 Individual adjustment to the blood obtained after animal injection and biodistribution studies with 188 Re-Anti-CD20 compared to the labeling of the same antibody with the other radionuclides [5,7,21,22] J Radioanal Nucl Chem for dosimetry; desired dose; volume of the tumor; time since the radionuclide production; initial activity; type of the tumor; type of the radionuclide.…”

“…The present work aims to evaluate the effectiveness of 188 Re-anti-CD20 in relation to its pharmacokinetic and dosimetry, based specifically on biodistribution data extracted from literature studies [5,7,21,22]. No experiments on animals were carried out in the present work.…”

“…The evaluation of the pharmacokinetic of the radiopharmaceuticals was assessed by defining a compartmental model for the antibody. All values presented in this work for biodistribution studies were extracted from published studies [5,7,21,22].…”

“…Actually, two radiopharmaceuticals prepared with Anti-CD20 FDA have approval for treatment of NHL: 131 IAntiCD20 (Bexar Ò ) and 90 Y-AntiCD20 (Zevalin Ò ) [5]. Techniques for radiolabeling anti-CD20 have been developed with 188 Re [6,7] to evaluate the clinical use of this radionuclide in particular.…”

Chelating agents for radiolanthanides: Applications to imaging and therapy

“…124 A more rapid and reliable radiolabelling method with 177 Lu has been subsequently reported. 125 DTPA conjugates with rituximab are also well known and have been radiolabelled with a range of radionuclides including 99m Tc 126 and 67 Ga. 127 Research on the 177 Lu-CHX-A''-DTPArituximab is well developed and animal studies have shown promising tumour uptake and targeting. 128 153 Sm-DTPA-rituximab has also been reported and was used to obtain SPECT images on rats 129 and Beyer et al have described the synthesis and use of 149 Tb-CHX-A"-DTPA complexes in the formation of conjugates with the antibody rituximab.…”